NEUPOGEN Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NEUPOGEN
| High Confidence Patents: | 5 |
| Applicants: | 1 |
| BLAs: | 1 |
| Drug Prices: | Drug price information for NEUPOGEN |
| Recent Clinical Trials: | See clinical trials for NEUPOGEN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NEUPOGEN |
Recent Clinical Trials for NEUPOGEN
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 1 |
| Newlife Fertility Centre | Phase 4 |
| St. Jude Children's Research Hospital | Phase 1/Phase 2 |
Recent Litigation for NEUPOGEN
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Pandora Marketing LLC | 2024-01-31 |
| JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD. | 2023-01-19 |
| JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC. | 2021-07-28 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2016-09-15 | |
| 2012-09-25 |
Pharmacology for NEUPOGEN
| Physiological Effect | Increased Myeloid Cell Production |
| Established Pharmacologic Class | Leukocyte Growth Factor |
| Chemical Structure | Granulocyte Colony-Stimulating Factor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NEUPOGEN Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NEUPOGEN Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2006-03-07 | Company disclosures |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | Company disclosures | |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | Company disclosures | |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2013-12-03 | Company disclosures |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2013-12-10 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NEUPOGEN Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2039-02-26 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2034-11-21 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2034-04-01 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2039-02-26 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2031-04-20 | Patent claims search |
| Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | ⤷ Sign Up | 2036-04-01 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for NEUPOGEN
Supplementary Protection Certificates for NEUPOGEN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014C/004 | Belgium | ⤷ Sign Up | PRODUCT NAME: LIPEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/13/856 20130725 |
| 2014/005 | Ireland | ⤷ Sign Up | PRODUCT NAME: LONQUEX-LIPEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/13/856 20130725 |
| 5/2003 | Austria | ⤷ Sign Up | PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822 |
| CR 2014 00003 | Denmark | ⤷ Sign Up | PRODUCT NAME: LIPEGFILGRASTIM; REG. NO/DATE: EU/1/13/856 20130729 |
| SPC/GB14/009 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729 |
| 10299044 | Germany | ⤷ Sign Up | PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822 |
| 92359 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LIPEGFILGRASTIM |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
